MBRX

Moleculin Biotech, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-18

Figures on this page computed 2026-11-08 12:40 UTC

Last close

8.46USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-18

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-18
The filing itself
-387.0%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
0.02Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital is the furthest below its sector's middle: 0.03 against 0.25 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

n/a

1.76x

1.29x

1.13x

0.00x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-18

Salesn/a
Its own average over 10 years, 0.
Profit1.76x
Its own average over 10 years, -19.0M.
Free cash flow1.29x
Its own average over 10 years, -17.6M.
Debt1.13x
Its own average over 9 years, 317.2K.
Price0.00x
Its own average over 6 years, 4.4K. Market data, 2026-11-04

Price is furthest from its own average, at 0.00 times.

Profit is 1.76 times its own 10-year average; Free cash flow is 1.29 times its own 10-year average; Debt is 1.13 times its own 9-year average; Price is 0.00 times its own 6-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-18

Sales against its own 10-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
The filing itself
Profit against its own 10-year average1.76
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
The filing itself
Free cash flow against its own 10-year average1.29
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
The filing itself
Debt against its own 9-year average1.13
Source
filed
Statement
income
Fiscal year
2025
Accession
0001437749-26-008841
Reported in
USD
The filing itself
Price against its own 6-year average0.002Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD